Nov. 13 (Bloomberg) -- Pfizer Inc. and Bristol-Myers Squibb Co.’s experimental drug apixaban wasn’t safer or more effective than a standard treatment in stopping blood clots in the legs and lungs of patients after hospitalization, a study found.
The trial, reported today at the American Heart Association meeting in Orlando, Florida, is the second to show new anticoagulants don’t provide a benefit in severely ill patients more than Sanofi’s injected drug Lovenox, the current standard. Johnson & Johnson and Bayer AG’s Xarelto failed to beat the standard therapy in a trial reported last April.
The potentially deadly clots occurred in 2.7 percent of those given apixaban, also known by the brand name Eliquis, compared with 3.1 percent of those given Lovenox, the results showed. The difference wasn’t statistically significant, researchers said. While the drugs’ benefits increased over time, both also triggered more major bleeding.
Sunday, November 13, 2011
Pfizer-Bristol Drug Doesn’t Cut Clots After Hospital Stays - Businessweek
via businessweek.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment